Höti Naseruddin, Li Ying, Chen Chien-Lun, Chowdhury Wasim H, Johns David C, Xia Qinghua, Kabul Arup, Hsieh Jer-Tsong, Berg Michael, Ketner Gary, Lupold Shawn E, Rodriguez Ronald
James Buchanan Brady Urology Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-2101, USA.
Mol Ther. 2007 Aug;15(8):1495-503. doi: 10.1038/sj.mt.6300223. Epub 2007 Jun 12.
Conditionally replication competent adenoviruses (CRAds) represent one of the most intensely studied gene therapy strategies for a variety of malignancies, including prostate cancer. These viruses can be generated by placing a tissue or cancer-specific promoter upstream of one or more of the viral genes required for replication (e.g., E1A, E1B). We report here that E1A inhibits androgen receptor (AR) target gene induction and, correspondingly, activated AR inhibits adenoviral replication. This mutual inhibition appears to be an indirect effect, possibly through competition for shared transcriptional co-activators. The net effect is that the oncolytic effect of prostate-specific CRAds is attenuated by these interactions. Fusion of the E1A to AR ameliorates this inhibition, while enhancing specificity. These findings have significant implications in the development of prostate-specific CRAd therapies.
条件性复制缺陷型腺病毒(CRAds)是针对包括前列腺癌在内的多种恶性肿瘤研究最为深入的基因治疗策略之一。这些病毒可通过将组织或癌症特异性启动子置于复制所需的一个或多个病毒基因(如E1A、E1B)的上游来产生。我们在此报告,E1A抑制雄激素受体(AR)靶基因的诱导,相应地,活化的AR抑制腺病毒复制。这种相互抑制似乎是一种间接效应,可能是通过竞争共享的转录共激活因子。其净效应是,这些相互作用减弱了前列腺特异性CRAds的溶瘤作用。将E1A与AR融合可改善这种抑制作用,同时增强特异性。这些发现对前列腺特异性CRAd疗法的开发具有重要意义。